Ets2 transcription factor in normal and neoplastic human breast tissue.
暂无分享,去创建一个
M. Duffy | E. McDermott | N. O’higgins | Y. Buggy | T. Maguire | A. Hill | M. Duffy | M J Duffy | A D K Hill | N O'Higgins | Y Buggy | T M Maguire | E McDermott | A. Hill
[1] C. Hauser,et al. Changes in the Expression of Many Ets Family Transcription Factors and of Potential Target Genes in Normal Mammary Tissue and Tumors* , 2004, Journal of Biological Chemistry.
[2] K. Fujikawa,et al. The Ets‐1 and Ets‐2 transcription factors activate the promoters for invasion‐associated urokinase and collagenase genes in response to epidermal growth factor , 1998, International journal of cancer.
[3] R. Cardiff,et al. Ets2-Dependent Stromal Regulation of Mouse Mammary Tumors , 2003, Molecular and Cellular Biology.
[4] B. Wasylyk,et al. The Ets family of transcription factors. , 1993, European journal of biochemistry.
[5] R. Tozer,et al. Expression of Ets-related Transcription Factors and Matrix Metalloproteinase Genes in Human Breast Cancer Cells , 2002, Breast Cancer Research and Treatment.
[6] J. Chambard,et al. The Ets2 Transcription Factor Inhibits Apoptosis Induced by Colony-Stimulating Factor 1 Deprivation of Macrophages through a Bcl-xL-Dependent Mechanism , 1999, Molecular and Cellular Biology.
[7] N. Brünner,et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.
[8] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[9] M. Hung,et al. The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis , 2000, Nature Medicine.
[10] V. Sementchenko,et al. ETS2 function is required to maintain the transformed state of human prostate cancer cells , 1998, Oncogene.
[11] Michael C. Ostrowski,et al. Ets-2 and Components of Mammalian SWI/SNF Form a Repressor Complex That Negatively Regulates the BRCA1Promoter* , 2003, The Journal of Biological Chemistry.
[12] C. Sweep,et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.
[13] Michael C. Ostrowski,et al. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis , 2005, Oncogene.
[14] J. Hassell,et al. Function of PEA3 Ets Transcription Factors in Mammary Gland Development and Oncogenesis , 2003, Journal of Mammary Gland Biology and Neoplasia.
[15] B. Wasylyk,et al. Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. , 1998, Trends in biochemical sciences.
[16] Margaret Kasten,et al. Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity , 2001, Oncogene.
[17] R. Cardiff,et al. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. , 1999, Cancer research.
[18] J. Tentler,et al. ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells , 2004, Oncogene.
[19] Michael C. Ostrowski,et al. ets-2 Is a Target for an Akt (Protein Kinase B)/Jun N-Terminal Kinase Signaling Pathway in Macrophages ofmotheaten-viable Mutant Mice , 2000, Molecular and Cellular Biology.
[20] M. Duffy,et al. Overexpression of the Ets-1 transcription factor in human breast cancer , 2004, British Journal of Cancer.
[21] N. Brünner,et al. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients , 2003, Thrombosis and Haemostasis.
[22] E. McDermott,et al. Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer , 2005, Clinical Cancer Research.
[23] Michael C. Ostrowski,et al. Persistent Activation of Mitogen-Activated Protein Kinases p42 and p44 and ets-2 Phosphorylation in Response to Colony-Stimulating Factor 1/c-fms Signaling , 1998, Molecular and Cellular Biology.
[24] David E. Misek,et al. Discordant Protein and mRNA Expression in Lung Adenocarcinomas * , 2002, Molecular & Cellular Proteomics.
[25] G. Viglietto,et al. Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. , 2001, Cancer research.
[26] L. Khachigian,et al. Ets-1 Protects Vascular Smooth Muscle Cells from Undergoing Apoptosis by Activating p21WAF1/Cip1 , 2003, Journal of Biological Chemistry.
[27] G. Peters,et al. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence , 2001, Nature.
[28] B. Vandenbunder,et al. Expression of the transcription factor c-Ets1 correlates with the occurrence of invasive processes during normal and pathological development. , 1994, Invasion & metastasis.
[29] C. Sweep,et al. Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer , 2002, Oncogene.
[30] Y. De Launoit,et al. The PEA3 group of ETS-related transcription factors. Role in breast cancer metastasis. , 2000, Advances in experimental medicine and biology.
[31] M. Duffy. Urokinase Plasminogen Activator and Its Inhibitor, Pai-1, as Prognostic Markers in Breast Cancer: from Pilot to Level 1 Evidence Studies , 2002 .
[32] E. Lengyel,et al. Stimulation of 92-kDa Gelatinase B Promoter Activity by ras Is Mitogen-activated Protein Kinase Kinase 1-independent and Requires Multiple Transcription Factor Binding Sites Including Closely Spaced PEA3/ets and AP-1 Sequences (*) , 1996, The Journal of Biological Chemistry.